세계의 고처리량 스크리닝(HTS) 시장 : 인사이트, 경쟁 환경, 시장 예측(-2032년)

High-Throughput Screening Market by Product (Instruments, Reagents and Kits, and Software), Technology (Cell-Based Assays, Ultra-High-Throughput Screening, Lab-On-A-Chip Technology, Label-Free High-Throughput Screening, and Next-Generation Sequencing (NGS), Application (In Vitro ADME Analysis, Drug Discovery & Development, Therapeutic Drug Monitoring, Lead Optimization, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product development by key players

The high-throughput screening market is estimated to grow at a CAGR of 10.61% during the forecast period from 2025 to 2032. The global high-throughput screening market is expected to grow a rapid pace due to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product developments by key players. Increasing technological advancements in drug discovery and the growing demand of precision medicine are some of the key factors contributing to propel the market expansion. Additionally, the increasing funding to accelerate drug discovery is also a key factor responsible for contributing to the positive growth of the high-throughput screening market during the forecast period from 2025 to 2032.

High-Throughput Screening Market Dynamics:

According to the data provided by the Centers for Disease Control and Prevention (CDC) published in February 2024, an estimated 129 million people were suffering from at least 1 major chronic disease such as heart disease, cancer, diabetes, obesity, and hypertension in the United States as of 2024. Cancer is a major chronic disease affecting people around the world. As per the study conducted by the International Agency for Research on Cancer in December 2020, mentioned, an estimated 19.3 million new cancer cases were reported in 2020 across the globe.

According to data cited by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 globally. HTS has the potential to uncover innovative targeted treatments, chemotherapy options, or immune system-regulating medications for various cancer types. Additionally, it aids in pinpointing combinations of drugs that work together synergistically, as well as crafting personalized treatment plans tailored to the unique molecular characteristics of individual tumors.

The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the high-throughput screening (HTS) market, as HTS assays can target essential microbial enzymes or pathways involved in pathogen replication, virulence, or host-cell interactions to identify potential drug targets and lead compounds. According to the World Health Organization (WHO) in 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally. Therefore, the increasing number of cases of infectious diseases will further increase the demand for diagnosis, thus contributing to market growth.

The rising research collaborations among key players are bolstering market growth due to the extensive use of HTS assays and instruments. These players are developing innovative smart assays to offer early-stage drug discovery to identify novel drug targets and cellular pathways. For instance, in May 2023, Axxam S.p.A., announced that it entered into a research collaboration with Promega Corporation, to develop cutting-edge luminescence-based assays, both cell-free and cell-based, tailored for miniaturized and fully automated high-throughput screening (HTS) setups.

In September 2023, SCIEX, a US-based mass spectrometry and capillary electrophoresis solutions entered into a research partnership with HighRes Biosolutions for precision detection and quantification of molecules in drug discovery.

In September 2022, Illumina, Inc., a US-based biotechnology company launched NovaSeq X and NovaSeq X Plus developed for genomic drug discovery. The NovaSeq X Plus has the capacity to produce over 20,000 whole genomes annually, which is 2.5 times faster than previous sequencers. This significant increase in throughput speeds up genomic exploration and medical understanding, leading to advancements in disease comprehension and potentially revolutionizing patient care.

Technological advancements play a pivotal role in high-throughput screening due to rapid transformation in the drug discovery process. Artificial Intelligence (AI) has revolutionized high throughput screening (HTS) in drug discovery, markedly enhancing efficiency, precision, and predictive capacities during the initial phases of drug development. Such developments in the market drive the demand for high-throughput screening, which promises a positive growth outlook for the market during the forecast period.

However, the high cost associated with the instrumentation and drug discovery process, and complexities in the assay development process, among others are some of the key constraints that may limit the growth of the high-throughput screening market.

High-Throughput Screening Market Segment Analysis:

High-Throughput Screening Market by Product (Instruments, Reagents and Kits, and Software), Technology (Cell-Based Assays, Ultra-High-Throughput Screening, Lab-On-A-Chip Technology, Label-Free High-Throughput Screening, and Next-Generation Sequencing (NGS), Application (In Vitro ADME Analysis, Drug Discovery & Development, Therapeutic Drug Monitoring, Lead Optimization, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment, the cell-based assay category was estimated to generate the largest revenue share in the high-throughput screening market in 2024. This can be attributed to cell-based assays, which constitute over half of all high-throughput drug screenings, serving purposes such as target validation and assessing ADMET (absorption, distribution, metabolism, elimination, and toxicity) in the initial phases of drug discovery. Key players in the market are developing innovative screening workflow automation to develop effective cellular assays to enhance drug discovery. For instance, in February 2023, Agilent Technologies Inc., a US-based pharmaceutical and medical technology company launched the xCELLigence RTCA HT (real-time cell analysis high-throughput) platform seamlessly integrates with the BioTek BioSpa 8 Automated Incubator. The xCELLigence RTCA HT technology has played a pivotal role in enabling high-throughput, swift, and quantitative monitoring of cytopathic effect (CPE), serving as a valuable tool for evaluating neutralizing activity and potency.

In January 2024, BD, a US-based pharmaceutical and medical technology company announced its collaboration with Hamilton, a laboratory automation technology company to develop robotics-compatible reagent kits to facilitate greater standardization and minimize human error during large-scale single-cell multiomics experiments to reduce potential biases.

Further, cell-based assays are versatile tools utilized in biomedical research and drug discovery screening. They effectively measure cytotoxicity, biological activity, biochemical mechanisms, and off-target interactions, aiding in the efficient evaluation of compounds and their potential applications. Therefore, the extensive use of cell-based assays category in primary and secondary screening will contribute to the growth of the segment, thereby driving the growth of the overall high-throughput screening market during the forecast period.

North America is expected to dominate the overall High-Throughput Screening Market:

North America was estimated to account for the largest market share of the high-throughput screening market in 2024. This can be attributed to the rising number of patients suffering from chronic diseases such as cancer. The increasing government support and research funding and the presence of major players are some of the key driving factors contributing to the growth of the high-throughput screening market in North America.

One of the prominent factors supporting the growth of the North America high-throughput screening market is the extensive use of HTS assays in the identification and validation of tumor markers indicating cancer development. For instance, according to National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States. Additionally, as per the same source, prostate, lung, and colorectal cancer accounted for 43% of the cancer cases in men, and breast, lung, and colorectal making up to 50% of cancer cases in women. This indicates the huge need for early drug development for disease treatment, therefore leading to the growth of high-throughput screening market in the region.

As per the data published by to US Government Accountability Office in May 2023, The National Institutes of Health (NIH), an agency within the Department of Health and Human Services (HHS), stands as the primary public funder of biomedical research and development (R&D). Between fiscal years 2017 and 2021, NIH allocated USD 97 billion for basic research, USD 28 billion for clinical trials and associated endeavors, and USD 9 billion for the training of biomedical professionals, as part of its commitment to advancing biomedical R&D. Therefore, the increasing government support for R&D which requires high-throughput screening techniques for drug development is promoting the growth of the market in the region.

The presence of key players and the development of advanced technologies to enhance the drug discovery process is one of the key factors contributing to the growth of the market in the region. These players are leveraging innovative technologies to accelerate drug research and clinical trials. In February 2022, Thermo Fisher Scientific Inc., announced its partnership with Medidata. In this collaboration, Thermo Fisher's PPD clinical research business partnered with Medidata Acorn AI, the advanced analytics insights division of Medidata, to create PPD TrueCast. The comprehensive enterprise application merged vast patient recruitment and site performance data with predictive models and advanced analytics. Such development by key players is expected to foster the growth of the high-throughput screening market in North America.

High-Throughput Screening Market Key Players:

Some of the key market players operating in the high-throughput screening market include Agilent Technologies, Inc., Axxam S.p.A., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., PerkinElmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Promega Corporation, Aurora Biomed Inc., Illumina, Inc., Oxford Nanopore Technologies plc, Corning Incorporated, F. Hoffmann-La Roche Ltd, Sygnature Discovery, BPS Bioscience, Inc., Revvity, Charles River Laboratories, Hamilton Company, UPM Biomedicals, and others.

Recent Developmental Activities in the High-Throughput Screening Market:

• In November 2023, Axxam S.p.A. and Momentum Biotechnologies joined forces to offer distinctive drug discovery solutions tailored for biotechnology and pharmaceutical clients. Under this partnership, Axxam's meticulously curated chemical diversity library, consisting of 325,000 compounds, was accessible for high-throughput screening utilizing Momentum's mass spectrometry-based functional and binding assay platforms.
• In July 2023, Illumina Inc., a US-based biotechnology company announced the launch of DRAGEN(TM) software for the analysis of next-generation sequencing data has been unveiled. DRAGEN 4.2 builds upon its accuracy and renowned flexibility and scalability, empowering efficient workflows and the extraction of valuable insights from genomic data for the identification of genetic disease causes, drug discovery, and population genomics.
• In January 2023, Charles River Laboratories, Inc. completed the acquisition of SAMDI Tech, Inc., a prominent provider of high-quality, label-free high-throughput screening (HTS) solutions utilized in drug discovery research. By acquiring SAMDI Tech's cutting-edge, high-throughput screening technology, Charles River Laboratories is bolstering its drug discovery capabilities. This move enhanced its distinct capacity to act as an integrated partner, offering comprehensive support for early-stage drug research and development initiatives.

Key Takeaways from the High-Throughput Screening Market Report Study

• Market size analysis for current High-Throughput Screening Market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global High-Throughput Screening market.
• Various opportunities available for the other competitors in the High-Throughput Screening Market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current High-Throughput Screening market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for High-Throughput Screening market growth in the coming future?

Target audience who can be benefited from this High-Throughput Screening Market Report Study

• High-Throughput Screening product providers
• Research organizations and consulting companies
• High-Throughput Screening related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in High-Throughput Screening
• Various end-users who want to know more about the High-Throughput Screening Market and the latest technological developments in the High-Throughput Screening Market.

Frequently Asked Questions for the High-Throughput Screening Market:

1. What are High-Throughput Screening?

• High-throughput screening (HTS) is a technique employed in drug discovery and biomedical research to rapidly and efficiently evaluate a large number of chemical compounds or biological samples for specific biological activity. It enables researchers to screen thousands to millions of compounds in a short timeframe, aiding in the identification of potential drug candidates, understanding biological pathways, and discovering new therapeutic agents.

2. What is the market for High-Throughput Screening?

• The high-throughput screening market is estimated to grow at a CAGR of 10.61% during the forecast period from 2025 to 2032.

3. What are the drivers for the global High-Throughput Screening market?

• The global high-throughput screening market is expected to a rapid pace due to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product developments by key players. Increasing technological advancements in drug discovery and the growing demand of precision medicine are some of the key factors contributing to propel the market expansion. Additionally, the increasing funding to accelerate drug discovery is also a key factor responsible for contributing to the positive growth of the high-throughput screening market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global High-Throughput Screening market?)

• Some of the key market players operating in the high-throughput screening market include Agilent Technologies, Inc., Axxam S.p.A., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., PerkinElmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Promega Corporation, Aurora Biomed Inc., Illumina, Inc., Oxford Nanopore Technologies plc, Corning Incorporated, F. Hoffmann-La Roche Ltd, Sygnature Discovery, BPS Bioscience, Inc., Revvity, Charles River Laboratories, Hamilton Company, UPM Biomedicals, and others.

5. Which region has the highest share in the global High-Throughput Screening market?

• North America was estimated to account for the largest market share of the high-throughput screening market in 2024. This can be attributed to the rising number of patients suffering from chronic diseases such as cancer. The increasing government support and research funding and the presence of major players are some of the key driving factors contributing to the growth of the high-throughput screening market in North America.

Table of Contents

1. High-Throughput Screening Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. High-Throughput Screening Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. High-Throughput Screening Market Key Factors Analysis

• 5.1. High-Throughput Screening Market Drivers
  • 5.1.1. The rising prevalence of chronic and infectious disease
  • 5.1.2. Growing research collaborations and product developments by key players
  • 5.1.3. Increasing technological advancements in drug discovery
  • 5.1.4. Increasing funding to accelerate drug
• 5.2. High-Throughput Screening Market Restraints and Challenges
  • 5.2.1. High cost associated with instrumentation and drug discovery process
  • 5.2.2. Complexities in the assay development process
• 5.3. High-Throughput Screening Market Opportunity
  • 5.3.1. Integration of AI and machine learning in drug discovery
  • 5.3.2. Integration of data analytics

6. High-Throughput Screening Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. High-Throughput Screening Market Assessment

• 7.1. By Product
  • 7.1.1. Instruments
  • 7.1.2. Reagents and Kits
  • 7.1.3. Software
• 7.2. By Technology
  • 7.2.1. Cell-Based Assays
  • 7.2.2. Ultra-High-Throughput Screening
  • 7.2.3. Lab-On-A-Chip Technology
  • 7.2.4. Label-Free High-Throughput Screening
  • 7.2.5. Next-Generation Sequencing (NGS)
• 7.3. By Application
  • 7.3.1. In Vitro ADME Analysis
  • 7.3.2. Drug Discovery & Development
  • 7.3.3. Therapeutic Drug Monitoring
  • 7.3.4. Lead Optimization
  • 7.3.5. Others
• 7.4. By End-User
  • 7.4.1. Pharmaceutical And Biotechnology Companies
  • 7.4.2. Contract Research Organizations
  • 7.4.3. Academic and Government Institutes
  • 7.4.4. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.1.2. Canada High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.1.3. Mexico High-Throughput Screening Market Size in USD million (2022-2032)
  • 7.5.2. Europe
    • 7.5.2.1. France High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.2.2. Germany High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.2.3. United Kingdom High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.2.4. Italy High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.2.5. Spain High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.2.6. Rest of Europe High-Throughput Screening Market Size in USD million (2022-2032)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.3.2. Japan High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.3.3. India High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.3.4. Australia High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.3.5. South Korea High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.3.6. Rest of Asia-Pacific High-Throughput Screening Market Size in USD million (2022-2032)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.4.2. Africa High-Throughput Screening Market Size in USD million (2022-2032)
    • 7.5.4.3. South America High-Throughput Screening Market Size In USD Million (2022-2032)

8. High-Throughput Screening Market Company and Product Profiles

• 8.1. Agilent Technologies, Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Axxam S.p.A.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Danaher Corporation
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Bio-Rad Laboratories, Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Merck & Co., Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. PerkinElmer Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Tecan Trading AG
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Thermo Fisher Scientific Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Promega Corporation
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Aurora Biomed Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Illumina, Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Oxford Nanopore Technologies plc
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Corning Incorporated
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. F. Hoffmann-La Roche Ltd
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Sygnature Discovery
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. BPS Bioscience, Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Revvity
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Charles River Laboratories
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Hamilton Company
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. UPM Biomedicals
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us